Rebus Holdings Inc (RBSH)

[jwblue74]

Product Development of Mipsagargin

https://www.sec.gov/Archives/edgar/data/1421204/000161577417006918/s108227_10q.htm

Mipsagargin is a prodrug targeting the tumor vasculature that has therapeutic potential in a wide range of malignancies. However, hepatocellular carcinoma, with promising Phase II study results, is our most advanced indication and our initial continued clinical focus. We are actively seeking a potential development and commercialization partner at both multi-national and regional levels to assist with the development of mipsagargin through clinical trials in liver cancer. Our current product development plan of mipsagargin contemplates the following major initiatives:
?
Initiation of our next clinical trial in patients with advanced HCC which includes clinical dose optimization.
?
Continuation of ongoing business development discussions with potential development partners.
?
Continued evaluation of single agent mipsagargin and mipsagargin combinations in nonclinical studies of other PSMA expressing tumors through collaboration with leading researchers in oncology.

$NSPX